<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01600469</url>
  </required_header>
  <id_info>
    <org_study_id>99-2452A3</org_study_id>
    <nct_id>NCT01600469</nct_id>
  </id_info>
  <brief_title>NMDA-enhancing Agent for Treatment of Mild Cognitive Impairment and Mild Alzheimer's Disease</brief_title>
  <official_title>NMDA-enhancing Agent for Treatment of Mild Cognitive Impairment and Mild Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      NMDA activation plays an important role in learning and memory. NMDA receptors were found to
      decrease in the frontal lobe and hippocampus of Alzheimer's disease and mild cognitive
      function impairment. This study is a randomized, double-blind, placebo-controlled drug trial.
      All patients will be allocated randomly to 2 groups: (1) NMDA enhancer: DAOI-B group
      (starting dose: 250-500 mg/d); (2) placebo group. The study period is 24 weeks. The
      investigators hypothesize that DAOI-B may yield better efficacy than placebo for cognitive
      function in patients with mild cognitive impairment or mild Alzheimer's disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Alzheimer's disease assessment scale-cognitive subscale in week 8, 16 and 24</measure>
    <time_frame>Week 0, 8, 16, 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Mini Mental Status Examination at week 8, 16 and 24</measure>
    <time_frame>Week 0, 8, 16, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Instrumental Activities of Daily Living at week 8, 16 and 24</measure>
    <time_frame>Week 0, 8, 16, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Verbal learning and memory at week 24</measure>
    <time_frame>Week 0, 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Digit Span subtest of the Wechsler Memory Scale at week 24</measure>
    <time_frame>Week 0, 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>DAOI-B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DAOI-B</intervention_name>
    <description>250-1500 mg/day, oral, for 24 weeks</description>
    <arm_group_label>DAOI-B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo, oral, for 24 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of mild cognitive impairment or mild Alzheimer's

          -  MMSE between 17-26

          -  CDR 0.5 or 1

        Exclusion Criteria:

          -  Hachinski Ischemic Score &gt; 4

          -  substance abuse/dependence

          -  Parkinson disease

          -  epilepsy

          -  major depressive disorder

          -  dementia with psychotic features

          -  major physical illnesses

          -  severe visual or hearing impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hsien-yuan Lane, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Departments of Psychiatry, China Medical University Hospital, Taichung, Taiwan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>886</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2012</study_first_submitted>
  <study_first_submitted_qc>May 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2012</study_first_posted>
  <last_update_submitted>June 3, 2013</last_update_submitted>
  <last_update_submitted_qc>June 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>mild cognitive impairment</keyword>
  <keyword>NMDA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

